For those with Part D who arent sure of their eligibility for the GLP-1 Bridge Program, please talk to your doctors
For those looking at broader peptide protocols that include growth hormone, recovery, or inflammation management alongside cognitive optimization, the key is to ensure that the BDNF-boosting components do not interfere with other compounds
Anything that can increase muscle growth will be looked at by the FDA with scrutiny
In studies of GLP-1RA therapy in patients with T2DM, the most frequently reported ADRs tend to arise from the gastrointestinal system, with nausea, vomiting, and diarrhea occurring in up to 51%, 19%, and 20% of patients, respectively
[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Mitrakou A., Kelley D., Veneman T., Jenssen T., Pangburn T., Reilly J., Gerich J